Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pliant Therapeutics (PLRX) Receivables (2019 - 2024)

Pliant Therapeutics has reported Receivables over the past 6 years, most recently at $2.3 million for Q4 2024.

  • Quarterly Receivables fell 23.19% to $2.3 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was $2.3 million through Dec 2024, down 23.19% year-over-year, with the annual reading at $2.3 million for FY2024, 23.19% down from the prior year.
  • Receivables was $2.3 million for Q4 2024 at Pliant Therapeutics, down from $3.0 million in the prior quarter.
  • Over five years, Receivables peaked at $9.3 million in Q4 2020 and troughed at $1.6 million in Q3 2021.
  • The 5-year median for Receivables is $3.0 million (2022), against an average of $3.9 million.
  • Year-over-year, Receivables tumbled 77.42% in 2021 and then soared 240.5% in 2022.
  • A 5-year view of Receivables shows it stood at $9.3 million in 2020, then crashed by 74.32% to $2.4 million in 2021, then grew by 28.45% to $3.1 million in 2022, then dropped by 2.09% to $3.0 million in 2023, then decreased by 23.19% to $2.3 million in 2024.
  • Per Business Quant, the three most recent readings for PLRX's Receivables are $2.3 million (Q4 2024), $3.0 million (Q4 2023), and $2.0 million (Q3 2023).